Novavax

NVAX54

$7.36arrow_drop_up1.52%$0.11

NVAX54

$7.36

arrow_drop_up1.52%$0.11

Performance History

Key Stats
Open	$7.05
Prev. Close	$7.22
EPS	-2.41
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	6.83	7.16
52 Week Range	3.53	23.86

Ratios







EPS	-2.41

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Novavax (NVAX)

Novavax Inc (NVAX) is a biotechnology company that specializes in the development of vaccines for various infectious diseases. The company is focused on creating innovative vaccine candidates using its proprietary recombinant nanoparticle technology. NVAX stock has a volatile price history, with fluctuations driven by news events and market sentiment. Investors should be aware of the risks associated with investing in biotech stocks, as they can be highly speculative and subject to regulatory uncertainties.

As of the latest quote, NVAX stock is trading at $X per share, representing a market capitalization of $X billion. The stock has recently experienced a surge in trading volume, reflecting increased investor interest in the company. Novavax Inc has been in the news recently for its COVID-19 vaccine candidate, which has shown promising results in clinical trials. The company has received funding from various sources, including government grants and partnerships with other pharmaceutical companies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. John Charles Jacobs M.B.A.
Headquarters: Gaithersburg
Employees: 1992
Exchange: NASDAQ

Keep an eye on Novavax

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Novavax 's (NVAX) price per share?

The current price per share for Novavax (NVAX) is $7.36. The stock has seen a price change of $0.11 recently, indicating a 1.52% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Novavax (NVAX)?

For Novavax (NVAX), the 52-week high is $23.86, which is 224.18% from the current price. The 52-week low is $3.53, the current price is 108.5% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Novavax (NVAX) a growth stock?

Novavax (NVAX) has shown an average price growth of -6.65% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Novavax as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Novavax (NVAX) stock price performance year to date (YTD)?

As of the latest data, Novavax (NVAX) has a year-to-date price change of 46.32%. Over the past month, the stock has experienced a price change of -27.49%. Over the last three months, the change has been -43.21%. Over the past six months, the figure is -48.89%. Looking at a longer horizon, the five-year price change stands at 92.17%.

help

Is Novavax (NVAX) a profitable company?

Novavax (NVAX) has a net income of -$545.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 65.05% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -153.61% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $983.7M, although specific revenue growth data is currently not available. The gross profit is $639.94M. Operating income is noted at -$566.51M. Furthermore, the EBITDA is -$240.84M.

help

What is the market capitalization of Novavax (NVAX)?

Novavax (NVAX) has a market capitalization of $1.17B. The average daily trading volume is 7.11, indicating the stock's liquidity and investor engagement.

News

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm

NOVAVAX

FDA

CLINICAL HOLD

COVID-19-INFLUENZA COMBINATION

INFLUENZA VACCINE

Oct 23, 2024

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

How Bad Is This News for Novavax?

Should You Buy Novavax Stock After This Regulatory Win?

PREVENTIVE HEALTHCARE

Sep 6, 2024

2024 Market Research: Vaccines Market Projected to Reach USD 116.63 Billion by 2027 - Rising Disease Prevalence and Prophylactic Applications Fueling Growth

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Novavax (NVAX)

Keep an eye on Novavax

Frequently Asked Questions

What is Novavax 's (NVAX) price per share?

What is the 52-week high and low for Novavax (NVAX)?

Is Novavax (NVAX) a growth stock?

What is Novavax (NVAX) stock price performance year to date (YTD)?

Is Novavax (NVAX) a profitable company?

What is the market capitalization of Novavax (NVAX)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level